KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Holly J. Kramer, Raymond R. Townsend, Karen Griffin, Joseph T. Flynn, Daniel E. Weiner, Michael V. Rocco, Michael J. Choi, Matthew R. Weir, Tara I. Chang, Rajiv Agarwal, Srinivasan Beddhu

Research output: Contribution to journalArticle

Abstract

Hypertension is a modifiable risk factor for cardiovascular morbidity and mortality and reduction of elevated blood pressure (BP) remains an important intervention for slowing kidney disease progression. Over the past decade, the most appropriate BP target for initiation and titration of BP-lowering medications has been an area of intense research and debate within the clinical community. In 2017, the American College of Cardiology and the American Heart Association (ACC/AHA) in conjunction with several other professional societies released new hypertension guidelines based on data from a systematic review of clinical trials and observational data. While many of the recommendations in the ACC/AHA hypertension guideline are relevant to nephrology practice, BP targets and management strategies for patients receiving dialysis are not discussed. This Kidney Disease Outcomes Quality Initiative (KDOQI) commentary focuses largely on recommendations from the ACC/AHA hypertension guidelines that are pertinent to individuals at risk of chronic kidney disease or with non–dialysis-dependent chronic kidney disease. This KDOQI commentary also includes a brief discussion of the consensus statement regarding hypertension diagnosis and management for adults receiving maintenance dialysis published by the European Renal and Cardiovascular Medicine Working Group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension. Overall, we support the vast majority of the ACC/AHA recommendations and highlight select areas in which best diagnosis and treatment options remain controversial.

Original languageEnglish (US)
Pages (from-to)437-458
Number of pages22
JournalAmerican Journal of Kidney Diseases
Volume73
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

American Heart Association
Kidney Diseases
Cardiology
Guidelines
Hypertension
Blood Pressure
Chronic Renal Insufficiency
Dialysis
Kidney
Nephrology
Renal Dialysis
Disease Progression
Maintenance
Medicine
Clinical Trials
Morbidity
Transplants
Mortality
Research

Keywords

  • angiotensin receptor blocker (ARB)
  • angiotensin-converting enzyme inhibitor (ACEi)
  • antihypertensive medication
  • blood pressure (BP)
  • BP control
  • BP measurement
  • BP target
  • calcium channel blocker (CCB)
  • clinical practice guideline
  • evidence-based medicine
  • Hypertension
  • kidney disease
  • kidney disease progression
  • nephrology best practices
  • review
  • thiazide diuretic

ASJC Scopus subject areas

  • Nephrology

Cite this

Kramer, H. J., Townsend, R. R., Griffin, K., Flynn, J. T., Weiner, D. E., Rocco, M. V., ... Beddhu, S. (2019). KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. American Journal of Kidney Diseases, 73(4), 437-458. https://doi.org/10.1053/j.ajkd.2019.01.007

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. / Kramer, Holly J.; Townsend, Raymond R.; Griffin, Karen; Flynn, Joseph T.; Weiner, Daniel E.; Rocco, Michael V.; Choi, Michael J.; Weir, Matthew R.; Chang, Tara I.; Agarwal, Rajiv; Beddhu, Srinivasan.

In: American Journal of Kidney Diseases, Vol. 73, No. 4, 01.04.2019, p. 437-458.

Research output: Contribution to journalArticle

Kramer, HJ, Townsend, RR, Griffin, K, Flynn, JT, Weiner, DE, Rocco, MV, Choi, MJ, Weir, MR, Chang, TI, Agarwal, R & Beddhu, S 2019, 'KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline', American Journal of Kidney Diseases, vol. 73, no. 4, pp. 437-458. https://doi.org/10.1053/j.ajkd.2019.01.007
Kramer HJ, Townsend RR, Griffin K, Flynn JT, Weiner DE, Rocco MV et al. KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. American Journal of Kidney Diseases. 2019 Apr 1;73(4):437-458. https://doi.org/10.1053/j.ajkd.2019.01.007
Kramer, Holly J. ; Townsend, Raymond R. ; Griffin, Karen ; Flynn, Joseph T. ; Weiner, Daniel E. ; Rocco, Michael V. ; Choi, Michael J. ; Weir, Matthew R. ; Chang, Tara I. ; Agarwal, Rajiv ; Beddhu, Srinivasan. / KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. In: American Journal of Kidney Diseases. 2019 ; Vol. 73, No. 4. pp. 437-458.
@article{c39ebc6f340748768503760fc2a23054,
title = "KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline",
abstract = "Hypertension is a modifiable risk factor for cardiovascular morbidity and mortality and reduction of elevated blood pressure (BP) remains an important intervention for slowing kidney disease progression. Over the past decade, the most appropriate BP target for initiation and titration of BP-lowering medications has been an area of intense research and debate within the clinical community. In 2017, the American College of Cardiology and the American Heart Association (ACC/AHA) in conjunction with several other professional societies released new hypertension guidelines based on data from a systematic review of clinical trials and observational data. While many of the recommendations in the ACC/AHA hypertension guideline are relevant to nephrology practice, BP targets and management strategies for patients receiving dialysis are not discussed. This Kidney Disease Outcomes Quality Initiative (KDOQI) commentary focuses largely on recommendations from the ACC/AHA hypertension guidelines that are pertinent to individuals at risk of chronic kidney disease or with non–dialysis-dependent chronic kidney disease. This KDOQI commentary also includes a brief discussion of the consensus statement regarding hypertension diagnosis and management for adults receiving maintenance dialysis published by the European Renal and Cardiovascular Medicine Working Group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension. Overall, we support the vast majority of the ACC/AHA recommendations and highlight select areas in which best diagnosis and treatment options remain controversial.",
keywords = "angiotensin receptor blocker (ARB), angiotensin-converting enzyme inhibitor (ACEi), antihypertensive medication, blood pressure (BP), BP control, BP measurement, BP target, calcium channel blocker (CCB), clinical practice guideline, evidence-based medicine, Hypertension, kidney disease, kidney disease progression, nephrology best practices, review, thiazide diuretic",
author = "Kramer, {Holly J.} and Townsend, {Raymond R.} and Karen Griffin and Flynn, {Joseph T.} and Weiner, {Daniel E.} and Rocco, {Michael V.} and Choi, {Michael J.} and Weir, {Matthew R.} and Chang, {Tara I.} and Rajiv Agarwal and Srinivasan Beddhu",
year = "2019",
month = "4",
day = "1",
doi = "10.1053/j.ajkd.2019.01.007",
language = "English (US)",
volume = "73",
pages = "437--458",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

AU - Kramer, Holly J.

AU - Townsend, Raymond R.

AU - Griffin, Karen

AU - Flynn, Joseph T.

AU - Weiner, Daniel E.

AU - Rocco, Michael V.

AU - Choi, Michael J.

AU - Weir, Matthew R.

AU - Chang, Tara I.

AU - Agarwal, Rajiv

AU - Beddhu, Srinivasan

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Hypertension is a modifiable risk factor for cardiovascular morbidity and mortality and reduction of elevated blood pressure (BP) remains an important intervention for slowing kidney disease progression. Over the past decade, the most appropriate BP target for initiation and titration of BP-lowering medications has been an area of intense research and debate within the clinical community. In 2017, the American College of Cardiology and the American Heart Association (ACC/AHA) in conjunction with several other professional societies released new hypertension guidelines based on data from a systematic review of clinical trials and observational data. While many of the recommendations in the ACC/AHA hypertension guideline are relevant to nephrology practice, BP targets and management strategies for patients receiving dialysis are not discussed. This Kidney Disease Outcomes Quality Initiative (KDOQI) commentary focuses largely on recommendations from the ACC/AHA hypertension guidelines that are pertinent to individuals at risk of chronic kidney disease or with non–dialysis-dependent chronic kidney disease. This KDOQI commentary also includes a brief discussion of the consensus statement regarding hypertension diagnosis and management for adults receiving maintenance dialysis published by the European Renal and Cardiovascular Medicine Working Group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension. Overall, we support the vast majority of the ACC/AHA recommendations and highlight select areas in which best diagnosis and treatment options remain controversial.

AB - Hypertension is a modifiable risk factor for cardiovascular morbidity and mortality and reduction of elevated blood pressure (BP) remains an important intervention for slowing kidney disease progression. Over the past decade, the most appropriate BP target for initiation and titration of BP-lowering medications has been an area of intense research and debate within the clinical community. In 2017, the American College of Cardiology and the American Heart Association (ACC/AHA) in conjunction with several other professional societies released new hypertension guidelines based on data from a systematic review of clinical trials and observational data. While many of the recommendations in the ACC/AHA hypertension guideline are relevant to nephrology practice, BP targets and management strategies for patients receiving dialysis are not discussed. This Kidney Disease Outcomes Quality Initiative (KDOQI) commentary focuses largely on recommendations from the ACC/AHA hypertension guidelines that are pertinent to individuals at risk of chronic kidney disease or with non–dialysis-dependent chronic kidney disease. This KDOQI commentary also includes a brief discussion of the consensus statement regarding hypertension diagnosis and management for adults receiving maintenance dialysis published by the European Renal and Cardiovascular Medicine Working Group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension. Overall, we support the vast majority of the ACC/AHA recommendations and highlight select areas in which best diagnosis and treatment options remain controversial.

KW - angiotensin receptor blocker (ARB)

KW - angiotensin-converting enzyme inhibitor (ACEi)

KW - antihypertensive medication

KW - blood pressure (BP)

KW - BP control

KW - BP measurement

KW - BP target

KW - calcium channel blocker (CCB)

KW - clinical practice guideline

KW - evidence-based medicine

KW - Hypertension

KW - kidney disease

KW - kidney disease progression

KW - nephrology best practices

KW - review

KW - thiazide diuretic

UR - http://www.scopus.com/inward/record.url?scp=85062858448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062858448&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2019.01.007

DO - 10.1053/j.ajkd.2019.01.007

M3 - Article

VL - 73

SP - 437

EP - 458

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 4

ER -